Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

2.

Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.

Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y.

Biopharm Drug Dispos. 2013 Jan;34(1):45-78. doi: 10.1002/bdd.1823. Review.

PMID:
23115084
3.

Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions.

Shitara Y.

Drug Metab Pharmacokinet. 2011 Jun;26(3):220-7. doi: 10.2133/dmpk.DMPK-10-RV-094. Review.

4.

Impact of OATP transporters on pharmacokinetics.

Kalliokoski A, Niemi M.

Br J Pharmacol. 2009 Oct;158(3):693-705. doi: 10.1111/j.1476-5381.2009.00430.x. Review.

5.

Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.

Neuvonen PJ, Backman JT, Niemi M.

Clin Pharmacokinet. 2008;47(7):463-74. Review.

PMID:
18563955
6.

Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.

Smith NF, Figg WD, Sparreboom A.

Expert Opin Drug Metab Toxicol. 2005 Oct;1(3):429-45. Review.

PMID:
16863454
7.

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake.

Niemi M, Pasanen MK, Neuvonen PJ.

Pharmacol Rev. 2011 Mar;63(1):157-81. doi: 10.1124/pr.110.002857. Review.

8.
9.

In vitro evidence for the role of OATP and OCT uptake transporters in drug-drug interactions.

Kindla J, Fromm MF, König J.

Expert Opin Drug Metab Toxicol. 2009 May;5(5):489-500. doi: 10.1517/17425250902911463 . Review.

PMID:
19416085
10.
11.

The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia.

Keppler D.

Drug Metab Dispos. 2014 Apr;42(4):561-5. doi: 10.1124/dmd.113.055772. Review.

12.

Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.

Fahrmayr C, Fromm MF, König J.

Drug Metab Rev. 2010 Aug;42(3):380-401. doi: 10.3109/03602530903491683. Review.

PMID:
20100011
13.

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

Neuvonen PJ, Niemi M, Backman JT.

Clin Pharmacol Ther. 2006 Dec;80(6):565-81. Review.

PMID:
17178259
14.

Impact of genetic variation in OATP transporters to drug disposition and response.

Gong IY, Kim RB.

Drug Metab Pharmacokinet. 2013;28(1):4-18. Review.

15.

Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.

Tornio A, Neuvonen PJ, Niemi M, Backman JT.

Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):83-95. Review.

PMID:
27548563
16.

Transporter-mediated drug-drug interactions.

Müller F, Fromm MF.

Pharmacogenomics. 2011 Jul;12(7):1017-37. doi: 10.2217/pgs.11.44. Review.

PMID:
21787191
17.

Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.

Kivistö KT, Niemi M.

Pharm Res. 2007 Feb;24(2):239-47. Review.

PMID:
17177112
18.

Role of OATP transporters in the disposition of drugs.

Niemi M.

Pharmacogenomics. 2007 Jul;8(7):787-802. doi: 10.2217/14622416.8.7.787. Review.

PMID:
18240907
19.

Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.

Elsby R, Hilgendorf C, Fenner K.

Clin Pharmacol Ther. 2012 Nov;92(5):584-98. doi: 10.1038/clpt.2012.163. Review.

PMID:
23047648
20.

Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.

Barton HA, Lai Y, Goosen TC, Jones HM, El-Kattan AF, Gosset JR, Lin J, Varma MV.

Expert Opin Drug Metab Toxicol. 2013 Apr;9(4):459-72. doi: 10.1517/17425255.2013.759210. Review.

PMID:
23331046

Supplemental Content

Support Center